Bicalutamide (ICI-176334)

For research use only. Not for use in humans.

目录号:S1190 中文名称:比卡鲁胺

Bicalutamide (ICI-176334) Chemical Structure

CAS No. 90357-06-5

Bicalutamide (ICI-176334) 是一种androgen receptor (AR)拮抗剂,在LNCaP/AR(cs)细胞系中IC50为0.16 μM。Bicalutamide 可诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 892.47 现货
RMB 988.18 现货
RMB 3014.55 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Bicalutamide (ICI-176334)发表文献39篇:

产品安全说明书

Androgen Receptor抑制剂选择性比较

生物活性

产品描述 Bicalutamide (ICI-176334) 是一种androgen receptor (AR)拮抗剂,在LNCaP/AR(cs)细胞系中IC50为0.16 μM。Bicalutamide 可诱导自噬。
特性 Bicalutamide 和Enzalutamide联用治疗前列腺肿瘤已经进入二期临床实验阶段。
靶点
Androgen Receptor [1]
(LNCaP/AR(cs) cells)
0.16 μM
体外研究

Bicalutamide 经过一个拮抗剂到激活剂的转变,刺激AR活性。在缺乏合成雄激素R1881的情况下,Bicalutamide处理LNCaP/AR(cs)细胞,改变基因表达,与其记录的良好激活剂活性相符合。Bicalutamide诱导细胞增殖,这种作用存在剂量依赖性,且只部分抗R1881的效果。Bicalutamide 处理呀显著产生大量核AR,虽然比R1881处理的少。Bicalutamide通过诱导DNA在AR靶基因结合,而具有部分激活剂活性,且不完全抗 R1881的效果。在R1881存在时, Bicalutamide部分激活 VP16-AR调节的转录,指导AR 结合到DNA上。使用AR驱动的荧光素酶报告结构稳定整合到LNCaP/AR-luc细胞中。在R1881存在时, Bicalutamide只微弱且部分抗 VP16-AR调节的转录,IC50 为 0.35 μM。[1] 微摩尔 Bicalutamide显著降低集落形成,这种作用存在剂量依赖性。[2] 双重抑制 AR 和 mTOR信号通路产生进一步好处,在体外,Ridaforolimus-Bicalutamide联用作用于前列腺癌细胞,与单独药剂处理相比,产生协同抗增殖效果。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-453 cells NXL4dWN7TnWwY4Tpc44h[XO|YYm= MUjEbZNxdGGlZX3lcpQhd2ZiW{PIYXIyQDhzIH\yc40hSVJiaX6gbJVu[W5iTVTBMW1DNTR3MzDj[YxteyxiRVO1NF0{OSCwTR?= NF34PW4zOzdzM{W2Oy=>
LNCaP cells NF65Rm5HfW6ldHnvckBie3OjeR?= M4W5XWlvcGmkaYTpc44hd2ZiW{PIYU1FUFRiYnnu[Ilv\yC2bzDUPFc4SSCjbnTyc4dmdiC{ZXPldJRweiCxZjDMUmNiWCClZXzsd{whU2l;M{Wgcm0> MmLQNVU3ODN7NkC=
Freestyle293F cells NXz3TIZkTnWwY4Tpc44h[XO|YYm= NU\GUVl[UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgRY5lem:pZX6gdoVk\XC2b4KgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTnKnZYP0fYxmOjl|RjDj[YxteyxiSVO1NF0xNjB3NDFOwG0> NV;6c4xiOjNzOUm0O|c>
HEK293 cells MlPJSpVv[3Srb36gZZN{[Xl? NELDdoY{KGh? M2HxSmRqe3CuYXPlcYVvfCCxZjDbNVcu[WyyaHGtcYV1cHmuLUPIYY1q[m:uZYLvcoUh\nKxbTDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDNiaILzMEBKSzVyPUW0JI5O NV\XZ3RkOjJ|OUGwN|M>
MDA453 cells Ml3XSpVv[3Srb36gZZN{[Xl? MWLEbZNxdGGlZX3lcpQhd2ZiW{PIYWRJXCCocn;tJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJG1FSTR3MzDj[YxteyxiS3m9OlQhdk1? M{S2O|E5OjlzNkS0
human MDA-MB-453 cells MV3GeY5kfGmxbjDhd5NigQ>? MY\EbZNxdGGlZX3lcpQhd2ZiW{PIYWRJXCCocn;tJGFTKGmwIHj1cYFvKE2GQT3NRk01PTNiY3XscJMtKEmFNUC9OlQhdk1? M1XwZ|IxPTh2NkGw
COS1 cells M{nuUmZ2dmO2aX;uJIF{e2G7 NX7FeXhjSW62YXfvcol{fCCjY4Tpeol1gSCjZ3HpcpN1KHCVR{WteIFo\2WmIHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDU3MyKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDy[YNmeHSxcj3t[YRq[XSnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYomgRXIuemWpdXzheIVlKHKjdDDwdo9j[XOrbjDwdo9ud3SncjDmdoFodWWwdDDkdol3\W5iZnny[YZtgSCudXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwQVAvODh4OTFOwG0> NEnEW2MzPTZ2Nk[0PS=>
HeLa cells MXXGeY5kfGmxbjDhd5NigQ>? MV\BcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZHnofYRzd3Snc4Tvd5Rmem:wZTDpcoR2[2WmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuNVQh|ryP NF7lRmYyPzhyNEKyPS=>
CV1 cells Mm\2SpVv[3Srb36gZZN{[Xl? MkK0Rolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{NCCNaU2wMlE2OSEQvF2= NX3mXWJ5OTd{NUe4N|g>
monkey COS7 cells MlPVSpVv[3Srb36gZZN{[Xl? NVPtb497SmmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5ibX;ub4V6KEORU{egZ4VtdHNiYomge4hwdGViY3XscEBjcW6maX7nJIF{e2G7LDDLbV0xNjF3MTFOwG0> MmnmNVg1PDJ7MUK=
COS7 cells NVzzR4c6TnWwY4Tpc44h[XO|YYm= NXTweYZ2SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG4JO69VQ>? Ml;nNlIxQTR{N{m=
CHO-K1 cells MVHGeY5kfGmxbjDhd5NigQ>? MnWzNkBp M3ziSWRqe3CuYXPlcYVvfCCxZjDbN2hedWmkb3zldo9v\SCocn;tJIh2dWGwIFHSJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3ME2wMlIh|ryP MoPpNlA{QDF|NkG=
human HT-3 cell M{O3ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLzTY5pcWKrdHnvckBw\iCqdX3hckBJXC1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63N|E{PCEQvF2= MUHTRW5ITVJ?
human LNCAP cells NWjWRlRlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGHGZpI{KGSjeYO= M1PDS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvPzN{NzFOwG0> NXfQeWtxOjZyNE[zNVM>
human PC3 cells MY\GeY5kfGmxbjDhd5NigQ>? M37wSGRqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCSQ{OgZ4VtdHNuIFXDOVA:PC5|IN88US=> MoKyNlU2QTFyNk[=
human 22Rv1 cells NFfteppHfW6ldHnvckBie3OjeR?= NX;teYlVOyCmYYnz NYKzTG9FSW62YXfvcol{fCCjY4Tpeol1gSCjdDDhcoRzd2enbjDy[YNmeHSxcjDIPFc1YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hOjKUdkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCGSGStbY5lfWOnZDDj[YxtKGe{b4f0bEBi\nSncjCzJIRigXNiYomgW3NVNThiYYPzZZktKEmFNUC9OE43KM7:TR?= MXKyOFkxODV6OB?=
human CCF-STTG1 cell NGLm[JRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7VTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTRwOUK5Nlkh|ryP MXXTRW5ITVJ?
human SCC-25 cell MkfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fpXWlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUK1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xQDZ3NjFOwG0> MmOyV2FPT0WU
human MKN45 cell NWHmUG5lT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjR3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj65OlA2KM7:TR?= MV7TRW5ITVJ?
human ES5 cell Mn7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{TPNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD62NVE2PCEQvF2= NU\iUGxiW0GQR1XS
human SK-MEL-3 cell M3P1UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DTdWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yOU[0JO69VQ>? M33ze3NCVkeHUh?=
human PC-3 cell M1POVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\6e3JvUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvOjd7MTFOwG0> M1fCPXNCVkeHUh?=
human NOS-1 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPMTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlI6OTdizszN MYLTRW5ITVJ?
human LB1047-RCC cell MljFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFzzNpBKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMj6yOVMh|ryP NIrxNZpUSU6JRWK=
human CAMA-1 cell NWezTlJkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFe5N3VKdmirYnn0bY9vKG:oIHj1cYFvKEODTVGtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjN7Mk[g{txO M1P0dXNCVkeHUh?=
human SAS cell NVTKZ4k5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHPOYRIUW6qaXLpeIlwdiCxZjDoeY1idiCVQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{4{ODhzIN88US=> NVXZV5FvW0GQR1XS
human NCI-H2228 cell NVK3UGxLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nyO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTNwN{WzNUDPxE1? MnPXV2FPT0WU
human NCI-H187 cell Mnv3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml31TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjZ4MU[g{txO MoLNV2FPT0WU
human BFTC-905 cell M4nHTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;sVJBKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTdwNEi1O{DPxE1? MmfrV2FPT0WU
human G-361 cell NUXZ[YQ1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NInySI5KdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVcvQDJ4IN88US=> M{XOfXNCVkeHUh?=
human DU145 cells Mne4R5l1d3SxeHnjxsBie3OjeR?= MUC3NkBp MULDfZRwfG:6aXPpeJkh[WejaX7zeEBGWmGucHjhMYRm\mmlaXXueEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEWUYnX0ZUBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE5KM7:TR?= M33ITnNCVkeHUh?=
human SW780 cell MmnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjneIxzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 Ml\OV2FPT0WU
human BB49-HNC cell NHexeZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;hRVJKdmirYnn0bY9vKG:oIHj1cYFvKEKENEmtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OThwOUWzNkDPxE1? M3XKO3NCVkeHUh?=
human KALS-1 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\yPWlvcGmkaYTpc44hd2ZiaIXtZY4hU0GOUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPjZ|NTFOwG0> MoHiV2FPT0WU
human AU565 cell M3LwT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXTlU4tjUW6qaXLpeIlwdiCxZjDoeY1idiCDVUW2OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6Njd2MEKg{txO NFnQbopUSU6JRWK=
human NCI-H2087 cell NGfncXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEH0cJBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJzLkC1PVEh|ryP MUDTRW5ITVJ?
human RVH-421 cell MlzrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHJXUC12MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU42Pzl3IN88US=> MVXTRW5ITVJ?
human SK-CO-1 cell MmLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV23N|B1UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3DU{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEi3NkDPxE1? NYm0TGQ2W0GQR1XS
human KU-19-19 cell M{nqTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\2TY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIzNjB{NEKg{txO M1zpW3NCVkeHUh?=
human NB6 cell NFnI[4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHL1N5NKdmirYnn0bY9vKG:oIHj1cYFvKE6ENjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKyMlkyOzVizszN NWP1UXBFW0GQR1XS
human RO82-W-1 cell MnPBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\rTY5pcWKrdHnvckBw\iCqdX3hckBTVzh{LWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjF|MUig{txO MnzDV2FPT0WU
human LNCAP cells MYTDfZRwfG:6aXRCpIF{e2G7 NILGWYIzKGSjeYO= Mom3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgNkBl[Xm|IHL5JINmdGxiY3;1cpRqdmdibXX0bI9lNCCLQ{WwQVI{Njd7IN88US=> MlnPNlM4OjdyNES=
human CTB-1 cell NHvXW2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnNcZN7UW6qaXLpeIlwdiCxZjDoeY1idiCFVFKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1NjV3M{[g{txO MWDTRW5ITVJ?
human SW48 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{T0UWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0MlY2PDZizszN M3n3eXNCVkeHUh?=
human TCCSUP cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHRES1OXUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0MlczOzJizszN MV3TRW5ITVJ?
human DK-MG cell M173Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnn5TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlg6OTdizszN MYTTRW5ITVJ?
human ST486 cell NFXyS29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4nEc2lvcGmkaYTpc44hd2ZiaIXtZY4hW1R2OE[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOU44PDZ2IN88US=> MlzzV2FPT0WU
human H4 cell NVLxWHQyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHnEUIdKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mk[uPVQ2QCEQvF2= MkPOV2FPT0WU
human SBC-1 cell Mk[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGHwTmtKdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvOzVyNzFOwG0> MnvPV2FPT0WU
human CAS-1 cell NU[5fWFpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXKwSoJwUW6qaXLpeIlwdiCxZjDoeY1idiCFQWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjZ{OUSg{txO M1;lcnNCVkeHUh?=
human OAW-42 cell M1\vWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUnUPJJ{UW6qaXLpeIlwdiCxZjDoeY1idiCRQWetOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQC55MUm1JO69VQ>? MlLsV2FPT0WU
human HCC1954 cell NV3SRoNkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2HLSGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUm1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5Njd3MkWg{txO MV;TRW5ITVJ?
human MDA-MB-453 cell NWe4e|JRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWf4eHhqUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDV|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuPVA4KM7:TR?= MVjTRW5ITVJ?
human MCF7 cell Mn;hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|OT6zNFEh|ryP NV\kUIRbW0GQR1XS
human PC3 cells MWjGeY5kfGmxbjDhd5NigQ>? MlfmNVAx64DCzszN NFrlN5A1QCCq MWHJcohq[mm2aX;uJI9nKGGldHnuJIJie2WmIIDz[ZVld3CxZHnhJIZwem2jdHnvckBqdiCjbnTyc4dmdi2mZYDlcoRmdnRiaIXtZY4hWEN|IHPlcIx{KGG2IEGwNEB2VSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgcYlkem:|Y3;wfUBie3OjeR?= MljSNlI3PzJ7OES=
human PC3 cells M3njc2Z2dmO2aX;uJIF{e2G7 M4DCcFAvOS1zIN88US=> MVvB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJHc4PDGFIH31eIFvfCCneIDy[ZN{\WRiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJN1cW23bHH0bY9vKG:oIILlZ4VxfG:{IITyZY5{[WO2aY\heIlwdiCjdDCwMlEhfG9iMTD1UUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= MVSyNlE4PTZ7NB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cytosolic AR / Nuclear AR ; 

PubMed: 30833616     


The representative expressions and the quantifications of proteins regarding the bicalutamide-induced apoptosis. (a) downregulation of nuclear androgen receptor (nAR).

30833616
Growth inhibition assay
Cell viability; 

PubMed: 27994514     


MDA-MB-231 and HCC1937 cells were treated with 10 μM bicalutamide and 10μM ABT-888 alone or in combination for 24h, 48h, 72h, and cell viability was determined by MTT assay.

27994514
体内研究 Bicalutamide按规定的次最大剂量单独处理,降低79%肿瘤生长。Ridaforolimus-Bicalutamide 联用具有改进的和有效的抗肿瘤活性,几乎完全废除肿瘤生长。联合使用具有良好耐受性,在处理过程中体重没有明显改变。联用处理的小鼠中,血浆PSA水平与肿瘤生长紧密相关。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

Whole-cell competitive binding assays:

Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.
细胞实验:[3]
- 合并
  • Cell lines: C4-2细胞系
  • Concentrations: 0 nM-1 μM
  • Incubation Time: 72小时
  • Method: 指数生长的C4-2细胞接种到96孔板中,在37oC下温育过夜。24小时后,吸除其中一个板,然后储存在-80oC中,其他使用10倍系列浓度 Ridaforolimus(1000 nM 到0.0001 nM)或乙醇(对照)处理。在 37oC下培养72小时,使用Cy qUANT细胞增殖检测试剂盒测评细胞生长。
    (Only for Reference)
动物实验:[3]
- 合并
  • Animal Models: 携带C4-2细胞的雄性裸鼠
  • Dosages: 10 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL (199.82 mM)
Water Insoluble
Ethanol '5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 430.37
化学式

C18H14F4N2O4S

CAS号 90357-06-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04573231 Recruiting Drug: 18F-DCFPyL Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer University of Wisconsin Madison May 24 2021 Phase 2
NCT04443062 Recruiting Drug: 177Lu-PSMA-617 Prostate Cancer Radboud University|Prostaatkankerstichting|Advanced Accelerator Applications July 20 2020 Phase 2
NCT02910050 Unknown status Drug: Bicalutamide|Drug: Aromatase Inhibitor Breast Cancer Xu fei|Sun Yat-sen University January 2016 Phase 2
NCT02614859 Active not recruiting Drug: Bicalutamide|Drug: Metformin and Bicalutamide Cancer of Prostate Fox Chase Cancer Center|National Cancer Institute (NCI) December 1 2015 Phase 2
NCT02146937 Withdrawn Drug: Bicalutamide plus Finasteride- Combination therapy Detectable Prostate Nodules Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Androgen Receptor Signaling Pathway Map

相关Androgen Receptor产品

Tags: 购买Bicalutamide (ICI-176334) | Bicalutamide (ICI-176334) ic50 | Bicalutamide (ICI-176334)价格 | Bicalutamide (ICI-176334) DMSO溶解度 | 采购Bicalutamide (ICI-176334) | Bicalutamide (ICI-176334)生产 | Bicalutamide (ICI-176334) 小鼠 | Bicalutamide (ICI-176334)化学结构 | Bicalutamide (ICI-176334)分子量 | Bicalutamide (ICI-176334) molecular weight | Bicalutamide (ICI-176334)说明书 | Bicalutamide (ICI-176334)供应商 | Bicalutamide (ICI-176334)体内 | Bicalutamide (ICI-176334)细胞系 | Bicalutamide (ICI-176334)浓度 | Bicalutamide (ICI-176334) nmr | Bicalutamide (ICI-176334)核磁 | Bicalutamide (ICI-176334)半数抑制浓度 | Bicalutamide (ICI-176334)体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID